Skip to main content

For adults with moderate to severe hidradenitis suppurativa

Purple to pink gradient background

THE COSENTYX UNOREADY® PEN DESIGN MAKES IT AN EASY TO USE, ONCE-MONTHLY INJECTION WITH UP TO A 100% USER SATISFACTION RATING

Convenient to use, in the comfort of your home every 4 weeks

The recommended dose of COSENTYX for adults with moderate to severe hidradenitis suppurativa is 300 mg. To start, your doctor may prescribe 5 weekly loading doses. To continue after that, you only need to take COSENTYX every 4 weeks thereafter.

Convenient Dosing: The recommended dose of COSENTYX® hidradenitis suppurativa (HS) is 300mg.* Getting started on COSENTYX once weekly for 5 weeks. Staying on COSENTYX once every 4 weeks.

Use COSENTYX exactly as prescribed by your doctor. 

If your doctor decides that you or a caregiver may give your injections at home, you should receive training on the right way to prepare and inject COSENTYX. Do not try to inject COSENTYX yourself, until you or your caregiver have been shown how by your doctor.

If you continue to have HS symptoms, your dermatologist may prescribe COSENTYX every 2 weeks.

Based on a study in which all 37 participants using the UnoReady Pen reported being satisfied or very satisfied with the device at 28 weeks for patients with moderate to severe plaque psoriasis.

Each 300-mg dose is given as 1 injection of 300 mg or 2 injections of 150 mg under the skin.

The COSENTYX UnoReady® Pen is designed for comfortable use

300 mg UnoReady Pen showing concealed needle, viewing window, latex-free pull-off cap, with clear confirmation clicks and no button to press.
  • The UnoReady Pen is a single, 300-mg injection

  • Design is convenient and easy to use

  • The needle is hidden

  • The cap is not made with natural rubber latex

  • The majority of people experience no pain with the injection§

Download and print the step-by-step Instructions for Use so you can have them handy whenever you need them. For more information about using the UnoReady Pen or the Sensoready® Pen, download and print the Quick Tips Brochure.
 


§Based on a study in which 30 of 38 participants using the UnoReady Pen reported no pain with the injection at 12 weeks.

NiYondashay is an actual patient. Individual results may vary. NiYondashay was compensated for her time.

Individual results may vary. NiYondashay was compensated for her time.

“To me, self-injecting kind of gives me more of my own self. I'm able to take the time to inject, discard it, and then move on to whatever I need to do that day.”


– NiYondashay, actual patient

*Limitations apply. Subject to annual co-pay benefit limit. Offer not valid under Medicare, Medicaid, or any other federal or state programs. Novartis reserves the right to rescind, revoke, or amend this program without notice. Additional limitations may apply. See complete Terms & Conditions for details.